Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesClimb Bio Inc

Climb Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
11.11 USD 0.82 ( 7.97%)
Last update at 2026-11-09T15:42:00Z
VOLUME
273995
Market Cap
798.94M

Momentum Score

…

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.28
Low
11.54
High
52 Week Price Range
1.54
Low
18.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Climb Bio Inc (CLYM) are limited; available SEC filings and investor materials provide few operational details. The company appears to be an early-stage biopharmaceutical enterprise where long-term growth would depend on clinical progress, licensing or commercialization milestones and successful regulatory outcomes that could support future revenue. Investors may find exposure to potential upside from therapeutic development attractive but should consult company filings for definitive information.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.29
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-27.10%
Net Debt
-35.14M
ROCE
-42.23%
Diluted EPS TTM
-0.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.85M -73.90M -35.12M -45.24M -47.48M
Net income -59.85M -73.90M -35.12M -45.24M -47.48M
Selling general administrative 21.17M 16.02M 24.86M 18.92M 12.35M
Gross profit -0.10M - - - -
Reconciled depreciation 0.10M 0.00M - - -
Ebit -67.88M -82.02M - - -
Ebitda -67.79M -30.36M - - -
Depreciation and amortization 0.10M - - - -
Operating income -67.88M -82.02M -40.27M -45.13M -35.67M
Other operating expenses 67.88M 82.02M - - -
Interest income 8.32M 8.13M 4.62M 1.38M -
Net interest income 8.32M 8.13M 4.62M 1.38M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 67.79M 82.02M 40.27M 45.13M 35.67M
Cost of revenue 0.10M - - - -
Total other income expense net 8.03M 8.12M 0.54M -1.48M -11.81M
Net income from continuing ops -59.85M -73.90M -35.12M -45.24M -47.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 167.74M 217.19M 110.47M 134.99M 173.24M
Other current assets 4.77M 2.83M 0.59M 3.00M 0.85M
Total liab 7.27M 5.31M 2.87M 6.28M 6.04M
Total stockholder equity 160.47M 211.88M 107.60M 128.72M 167.20M
Other current liab 4.46M 4.07M 0.14M - -
Common stock 0.01M 0.01M - - -
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -289.73M -229.88M -155.98M -120.86M -75.62M
Cash 35.69M 87.23M 93.11M 43.59M 46.92M
Total current liabilities 6.98M 4.93M 2.83M 6.10M 6.03M
Net debt -35.14M -86.70M - - -
Short term debt 0.26M 0.16M - - -
Short long term debt total 0.54M 0.53M - - -
Other stockholder equity 449.76M 441.73M - - -
Total current assets 105.85M 154.87M 110.25M 134.39M 148.25M
Long term investments 59.57M 61.61M - 0.00M 24.92M
Short term investments 65.39M 63.69M 13.69M 79.98M 89.56M
Net receivables - 1.12M - - -
Accounts payable 2.27M 0.70M 0.07M 0.75M 1.40M
Accumulated other comprehensive income 0.43M 0.02M - - -
Non currrent assets other 1.53M 0.21M 0.01M 0.13M 0.07M
Non current assets total 61.89M 62.31M 0.21M 0.60M 24.99M
Capital lease obligations 0.54M 0.53M 0.35M 0.48M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.02M -121.09M 68.98M 34.44M -114.97M
Total cashflows from investing activities 2.83M -121.09M 68.98M 34.44M -114.97M
Total cash from financing activities -0.02M 130.73M 0.84M 0.00M 177.23M
Net income -59.85M -73.90M -35.12M -45.24M -47.48M
Change in cash -51.54M -5.88M 49.53M -3.34M 26.43M
Begin period cash flow 87.23M 93.11M 43.59M 46.92M 20.49M
End period cash flow 35.69M 87.23M 93.11M 43.59M 46.92M
Total cash from operating activities -54.36M -15.56M -20.60M -37.37M -36.07M
Issuance of capital stock 0.00M 119.75M 0.00M 0.00M 177.08M
Depreciation 0.10M 0.00M - - -
Other cashflows from investing activities - -9.64M - - -
Other cashflows from financing activities - 10.98M 0.84M - 94.09M
Capital expenditures 0.19M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.60M 1.70M 3.76M 0.21M -4.17M
Stock based compensation 8.05M 5.56M 12.81M 6.99M 3.74M
Other non cash items 6.00M 51.08M -2.05M 0.67M 11.84M
Free cash flow -54.54M -15.56M -20.60M -37.37M -36.07M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CLYM
Climb Bio Inc		 0.82
7.97%		 11.11 - - - 3.49 0.58
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Climb Bio Inc

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

20 William Street, Wellesley Hills, MA, United States, 02481

866 857 2596

https://climbbio.com

28

Name Title Year Born
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc CEO, President & Director 1976
Dr. Brett Kaplan M.B.A., M.D. COO & Principal Financial Officer 1974
Ms. Emily Pimblett Chief Accounting Officer 1984
Ms. Jo Palmer-Phillips Ph.D. Chief Development Officer NA
Dr. Nishi Rampal M.D. Senior Vice President of Clinical Development NA
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc CEO, President & Director 1977
Dr. Susan Altschuller M.B.A., Ph.D. Chief Financial Officer 1982
Ms. Cindy J. Driscoll M.B.A. Senior VP of Finance & Principal Accounting Officer 1966
Ms. Chandra Adams J.D. VP & General Counsel NA
Ms. Ashley Jones Senior VP of People & Workforce Strategy NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…